Remiges joined Series A1 Round of KisoJi Biotechnology in Montreal Canada

Remiges joined the Series A1 financing for KisoJi Biotechnologies Inc. a Canada-based biotechnology company focusing to develop oncology therapeutic agents based on its proprietary single-domain antibodies technology platform.

The proceeds from the investment will be used to finance the development of the company's platform technology as well as in-house programs.

In conjunction with the Series A1 financing Takaaki Tobaru from Remiges Ventures joined the board of directors of the firm, and moving forward Remiges anticipates supporting the firm's value creation.